NEW ORLEANS, June 6, 2026 /PRNewswire/ -- Today, from the main stage at the organization's 2026 Scientific Sessions, the American Diabetes Association® (ADA) announced...
New Study Highlights Potential of CGM to Help Patients Improve Diabetes Management in Primary Care SettingsNEW ORLEANS, June 6, 2026 /PRNewswire/ -- A new...
Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...
Pinellas Gulf Beach vacation rental and STR investment specialist places in the top 0.3% of residential real estate professionals in Florida, based on independently verified 2025 sales data
Pinellas Gulf Beach vacation rental and STR investment specialist places in the top 0.3% of residential real estate professionals in Florida, based on independently verified 2025 sales data
NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance (Nasdaq: AIFA) (“AIFA” or the “Company”) today provided a strategic update. Following the Company’s previously announced signing of agreements to acquire a controlling interest in HyalRoute Communication Group (“HyalRoute”) and advancement of the Hainan AIFA Silicon Photonics Supercomputing Center project, the Company is further accelerating project planning, policy coordination, financing arrangements, and cross-border resource integration around its dual-engine strategy of an “AI infrastructure network powered by optical technologies” and an “AI application services matrix.”
New research supports monthly dosing as a next‑generation opportunity to improve weight lossNEW ORLEANS, June 6, 2026 /PRNewswire/ -- New data highlight the potential...
Chandigarh University Sings MoU with Global Consulting Giant PwC to Offer Online MBA Program330 Postgraduate and 33 Undergraduate Degrees Conferred to Online and Distance...
Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...
A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...